

Appendix 3: Sensitivity analyses: indirect comparison of lixisenatide vs. NPH without consideration of the studies investigating exenatide or calculating the indirect comparison via insulin glargine as a reference

	Point estimate (MD, RR or OR)	95% CI on MD, RR or OR
HbA _{1c} (MD) – indirect comparison	0.07	[-0.263; 0.407]
HbA_{1c} (wo the exe pathway) (MD) – indirect comparison	0.08	[-0.288; 0.448]
HbA _{1c} (wo Apovian) (MD) – indirect comparison	0.17	[-0.121; 0.46]
HbA _{1c} at target (OR) – indirect comparison	0.58	[0.252; 1.319]
HbA _{1c} at target (RR) – indirect comparison	0.58	[0.305; 1.1]
HbA _{1c} at target (RR) – MTC	0.58	[0.305; 1.1]
Body Weight (MD) – indirect comparison	-3.62	[-5.859; -1.375]
Body weight (wo the exe pathway) (MD) – indirect comparison	-2.65	[-4.003; -1.297]
Hypos (OR) – indirect comparison	0.38	[0.165; 0.853]
Hypos (wo the exe pathway) (OR) – indirect comparison	0.50	[0.226; 1.093]
Hypos (RR) – indirect comparison	0.56	[0.324; 0.961]
Hypos (RR) – MTC	0.57	[0.292; 1.102]
Confirmed hypos (OR) – indirect comparison	0.46	[0.219; 0.958]
Confirmed Hypos (wo the exe pathway) (OR) – indirect comparison	0.56	[0.25; 1.244]
Confirmed hypos (RR) – indirect comparison	0.61	[0.334; 1.109]
Confirmed hypos (RR) – MTC	0.61	[0.318; 1.173]
Discontinuation for AEs (OR) – indirect comparison	2.64	[0.25; 27.956]
Discontinuation for AEs (OR) (wo the exe pathway) – indirect comparison	0.97	[0.08; 11.758]
Discontinuation for AEs (RR) – indirect comparison	2.52	[0.254; 25.019]
Discontinuation for AEs (RR) – MTC (random effects)	3.33	[0.117; 94.873]